Literature DB >> 16924493

CD1 expression and CD1-restricted T cell activity in normal and tumour-bearing human liver.

Tony Kenna1, Margaret O'Brien, Andrew E Hogan, Mark A Exley, Steven A Porcelli, John E Hegarty, Cliona O'Farrelly, Derek G Doherty.   

Abstract

CD1d-restricted natural killer T (NKT) cells expressing invariant Valpha14Jalpha18 T cell receptor alpha-chains are abundant in murine liver and are implicated in the control of malignancy, infection and autoimmunity. Invariant NKT cells have potent anti-metastatic effects in mice and phase I clinical trials involving their homologues in humans are ongoing. However, invariant NKT cells are less abundant in human liver ( approximately 0.5% of hepatic T cells) than in murine liver (up to 50%) and it is not known if other hepatic T cells are CD1-restricted. We have examined expression of CD1a, CD1b, CD1c and CD1d mRNA and protein in human liver and evaluated the reactivity of mononuclear cells (MNC) from histologically normal and tumour-bearing human liver specimens against these CD1 isoforms. Messenger RNA for all CD1 isotypes was detectable in all liver samples. CD1c and CD1d were expressed at the protein level by hepatic MNC. CD1d, only, was detectable at the cell surface, but CD1c and CD1d were found at an intracellular location in significant numbers of liver MNC. CD1b was not expressed by MNC from healthy livers but was detectable within MNC in all tumour samples tested. Hepatic T cells exhibited reactivity against C1R cells expressing transfected CD1c and CD1d, but neither CD1a nor CD1b. These cells secreted interferon-gamma (IFN-gamma) but not interleukin-4 (IL-4) upon stimulation. In contrast, similar numbers of peripheral T cells released 13- and 16-fold less IFN-gamma in response to CD1c and CD1d, respectively. CD1c and CD1d expression and T cell reactivity were not altered in tumour-bearing liver specimens compared to histologically normal livers. These data suggest that, in addition to invariant CD1d-restricted NKT cells, autoreactive T cells that recognise CD1c and CD1d and release inflammatory cytokines are abundant in human liver.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924493     DOI: 10.1007/s00262-006-0215-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

1.  Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C.

Authors:  K Yanagisawa; S Yue; H J van der Vliet; R Wang; N Alatrakchi; L Golden-Mason; D Schuppan; M J Koziel; H R Rosen; M A Exley
Journal:  J Viral Hepat       Date:  2013-03-11       Impact factor: 3.728

Review 2.  Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects.

Authors:  Mark A Exley; Lydia Lynch; Bindu Varghese; Michael Nowak; Nadia Alatrakchi; Steven P Balk
Journal:  Clin Immunol       Date:  2011-05-13       Impact factor: 3.969

3.  Harnessing CD1d-restricted T cells toward antitumor immunity in humans.

Authors:  Natalia Neparidze; Madhav V Dhodapkar
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

4.  Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.

Authors:  David H Chang; Haiteng Deng; Phillip Matthews; Joseph Krasovsky; Govind Ragupathi; Radek Spisek; Amitabha Mazumder; David H Vesole; Sundar Jagannath; Madhav V Dhodapkar
Journal:  Blood       Date:  2008-06-05       Impact factor: 22.113

5.  Analysis of the CD1 antigen presenting system in humanized SCID mice.

Authors:  Jennifer L Lockridge; Xiuxu Chen; Ying Zhou; Deepika Rajesh; Drew A Roenneburg; Subramanya Hegde; Sarah Gerdts; Tan-Yun Cheng; Regan J Anderson; Gavin F Painter; D Branch Moody; William J Burlingham; Jenny E Gumperz
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

Review 6.  Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives.

Authors:  Jing-Bo Wang; Xue Huang; Fu-Rong Li
Journal:  Cancer Commun (Lond)       Date:  2019-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.